CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

021876Orig1s000

Trade Name: Diclegis

Generic Name: doxylamine succinate and pyridoxine hydrochloride

Sponsor: Duchesnay Inc.

Approval Date: April 8, 2013

Indications: For the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

CENTER FOR DRUG EVALUATION AND RESEARCH

021876Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	
Labeling	**X**
REMS	
Summary Review	**X**
Officer/Employee List	**X**
Office Director Memo	
Cross Discipline Team Leader Review	**X**
Medical Review(s)	**X**
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	**X**
Statistical Review(s)	**X**
Microbiology Review(s)	**X**
Clinical Pharmacology/Biopharmaceutics Review(s)	**X**
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

021876Orig1s000

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021876

NDA APPROVAL

Duchesnay Inc.
c/o OptumInsight Life Sciences Inc.
Attention: John J.K. Killackey, Ph.D.
Director, US Regulatory Affairs
131 Morristown Road
Basking Ridge, NJ 07920

Dear Dr. Killackey:

Please refer to your New Drug Application (NDA) dated December 17, 2004, received April 18, 2005, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Diclegis (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets, 10 mg/10 mg.

We acknowledge receipt of your June 8, 2012, resubmission to the original application which was not filed. We also acknowledge your amendments dated June 11, 26, 28, July 12, 16, 17, 19, August 1, 3, 13, October 5, November 19, December 4, 5, 18, 2012, January 14, February 22, 26, 28, March 7, 8, 12, and April 8, 2013.

This new drug application provides for the use of Diclegis delayed-release tablets for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

Submit final printed carton and immediate-container labels that are identical to the enclosed carton and immediate-container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).* Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 021876**." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages birth through eleven years of age because necessary studies are impossible or highly impracticable. This is because pregnancy cannot occur in premenarchal girls who are in this age range (< 1- 11 years of age) and the number of girls at the upper ages in this range (9-11 years of age) who are able to become pregnant (postmenarchal) is too few.

We are deferring submission of your pediatric study for pregnant girls ages 12 to 17 years for this application because this product is ready for approval for use in adult pregnant women and the pediatric study has not been completed.

Your deferred pediatric study required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act (FDCA) is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. This required study is listed below.

2033-1 An adequately powered safety and efficacy study in pregnant adolescent girls, 12 to 17 years of age, with nausea and vomiting of pregnancy who are appropriate candidates for pharmacologic therapy.

Final protocol Submission:	January 2014
Study/Trial Completion:	January 2018
Final Report Submission:	July 2018

Submit the protocol to your IND 072300, with a cross-reference letter to this NDA.

Submit the draft protocol at least 3 months prior to the final protocol submission date to allow for review and agreement on the protocol design.

Reports of this required pediatric postmarketing study must be submitted as an NDA or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call George Lyght, Pharm.D., Sr. Regulatory Health Project Manager, at (301) 796-0948.

Sincerely,

{See appended electronic signature page}

Hylton V. Joffe, M.D., M.M.Sc.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

HYLTON V JOFFE
04/08/2013